Open an account

Scholar Rock Holding

SRRK · NASDAQ

$41.36+$1.12 (+2.78%)TodayMarket closed ·
Prev close $40.24

About SRRK

Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 289 full-time employees. The company went IPO on 2018-05-24. The firm focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.

Employees
289
Headquarters
Cambridge, Massachusetts
Listed
May 24, 2018
Sector
Health Care
Industry
Biotechnology
Website
scholarrock.com

SRRK key statistics

Market cap
5.04B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.97M
Volume
1.61M
Open price
$40.38
High today
$41.90
Low today
$40.29
52 Week high
$61.76
52 Week low
$27.07

Scholar Rock Holding (SRRK) at a glance

As of Oct 20, 2026, Scholar Rock Holding (SRRK) shares are priced at $41.36, giving the company a market cap of 5.04B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $40.29 and $41.90. The current price is 2.7% above the day's low and 1.3% below its high.

Volume so far is 1.61M shares, in line with the average of 1.97M shares a day.

Over the past year Scholar Rock Holding has ranged from $27.07 to $61.76, and now sits 41% of the way up that range.

Scholar Rock Holding met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.84 per share against an estimate of -$0.8572.

The average analyst price target is $70.44, 70.3% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

92%of 12 analyst ratings say Buy
  • Buy91.7%
  • Hold8.3%
  • Sell0.0%
Price target · 19 analystsAvg $70.44
Low
$48.48
Now
$41.36
High
$88.20

SRRK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 1.6% on average.

  1. Q3 FY24: reported -$0.66 per share against an estimate of -$0.6123
  2. Q4 FY24: reported -$0.61 per share against an estimate of -$0.6146
  3. Q1 FY25: reported -$0.67 per share against an estimate of -$0.6743
  4. Q2 FY25: reported -$0.98 per share against an estimate of -$0.6779
  5. Q3 FY25: reported -$0.90 per share against an estimate of -$0.8556
  6. Q4 FY25: reported -$0.88 per share against an estimate of -$0.9081
  7. Q1 FY26: reported -$0.83 per share against an estimate of -$0.8168
  8. Q2 FY26: reported -$0.84 per share against an estimate of -$0.8572

SRRK news

  • Press releaseBusiness Wire

    Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

  • Press releaseBusiness Wire

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

  • Press releaseBusiness Wire

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Vandana Singh

    Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

  • Press releaseBusiness Wire

    Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

  • FDA Approves First Therapy To Target Muscle Loss In Spinal Muscular Atrophy In Patients Aged 2 Years And Older

Similar companies

Companies in the same industry as Scholar Rock Holding

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.